Topic
Psilocybin, ketamine, ibogaine and MDMA: mechanism, trial status, and honest limits.
Psilocybin, ketamine, MDMA, and ibogaine are moving through regulatory pipelines at very different speeds, under very different safety profiles. We report trial phase, comparator, blinding limits, cardiac and psychiatric risk, and the difference between a supervised protocol and a clinic marketing one. Enthusiasm is not evidence, and neither is dismissal.
A Phase 3 programme produced some of the largest effect sizes in modern psychiatry. The regulator was not persuaded — and what it objected to was not, in the main, the effect size.
Revuelt Health · August 9, 2026 · 10 min read
Read
Observational data on opioid withdrawal is genuinely interesting. The cardiac risk profile is genuinely serious. Both facts have to be held at once.
Revuelt Health · July 14, 2026 · 11 min read
Read
The drug works quickly for some people with severe depression. What happens around the infusion varies enormously from clinic to clinic.
Revuelt Health · June 9, 2026 · 7 min read
ReadThe dispatch
Considered emails, never more than you want. Research, clinics, and what the evidence currently supports. No hype, no unsubscribing guilt.